Related Experiment Video
Updated: Oct 29, 2025

Implantation of Total Artificial Heart in Congenital Heart Disease
Published on: July 18, 2014
COVID-19 diagnosis and testing in pediatric heart transplant recipients
Matthew J Bock1, Micheal A Kuhn1, Richard E Chinnock1
1Pediatric Cardiology, Loma Linda University Children's Hospital, Loma Linda, California.
Insights
Pediatric heart transplant patients frequently contract COVID-19, but most infections are asymptomatic and well-tolerated, with a robust antibody response observed. Routine testing aids in early detection and prevents transmission.
Area of Science:
- Immunology
- Pediatric Cardiology
- Infectious Diseases
Background:
- Pediatric heart transplant recipients are considered at high risk for severe COVID-19 outcomes.
- Understanding COVID-19's impact in this vulnerable population is crucial for management.
Purpose of the Study:
- To evaluate the incidence, clinical presentation, and immune response to COVID-19 in pediatric heart transplant recipients.
- To assess the effectiveness of routine PCR and antibody testing in this cohort.
Main Methods:
- A cohort of pediatric heart transplant recipients underwent COVID-19 RNA PCR and antibody testing starting March 15, 2020.
- Outcomes of infected patients were retrospectively reviewed.
Main Results:
- COVID-19 infection occurred in 21% of the cohort, with 55% being asymptomatic.
- Despite immunosuppression, over 70% showed antibody seroconversion, persisting beyond 90 days.
- Only 5% required hospital admission, and 0% mortality was observed.
Conclusions:
- COVID-19 is common but generally well-tolerated in pediatric heart transplant recipients.
- These patients mount a significant and persistent antibody response to SARS-CoV-2.
- Routine COVID-19 testing is valuable for detecting asymptomatic infections and reducing transmission.
Abstract:
Pediatric heart transplant recipients have been expected to be at higher risk of adverse events from developing COVID-19 infection. COVID-19 RNA PCR and antibody testing has been performed in our cohort of patients since March 15, 2020 and outcomes were reviewed. COVID-19 infection in our population of pediatric heart transplant recipients is common (21%), despite recommendations to avoid contact with others. Asymptomatic COVID-19 infection is common as well (55%). Despite the frequency of infection, COVID-19 is well tolerated in this population (5% admission from home; 0% mortality). A suppressed immune system does not significantly inhibit an antibody response in pediatric heart transplant recipients (>70% antibody seroconversion) and appears to persist, similar to those without transplantation (>90 days). Routine testing for COVID-19 via PCR and antibody testing enhances the ability to detect COVID-19 infection in asymptomatic patients and may help reduce unintended transmission to more susceptible individuals.
Related Concept Videos
Kidney Transplant I: Introduction
Kidney Transplant II: Surgical Procedure
Myocarditis II: Clinical Features and Diagnostic Tests
Mitral Stenosis II: Clinical features and Diagnostic Tests
Cardiac Catheterization I: Pre-Procedure Overview

